{{Rsnum
|rsid=10116682
|Gene=PTPRD
|Chromosome=9
|position=8761778
|Orientation=plus
|GMAF=0.05234
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 0.0 | 0.9 | 99.1
| HCB | 0.0 | 8.9 | 91.1
| JPT | 0.0 | 4.5 | 95.5
| YRI | 1.4 | 24.0 | 74.7
| ASW | 0.0 | 22.8 | 77.2
| CHB | 0.0 | 8.9 | 91.1
| CHD | 0.0 | 3.7 | 96.3
| GIH | 0.0 | 1.0 | 99.0
| LWK | 0.9 | 36.4 | 62.7
| MEX | 0.0 | 3.4 | 96.6
| MKK | 2.6 | 16.7 | 80.8
| TSI | 0.0 | 4.9 | 95.1
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10116682
|Name_s=
|Gene_s=PTPRD
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: A, MAF= 0.04, combined P value= 1.63E-05.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470164
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10116682
|overall_frequency_n=9
|overall_frequency_d=128
|overall_frequency=0.0703125
|n_genomes=9
|n_genomes_annotated=0
|n_haplomes=10
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}